Healthcare Weekly Losers: Ultragenyx Pharmaceutical (NASDAQ:RARE), Retrophin Inc (NASDAQ:RTRX), Arrowhead Research Corp (NASDAQ:ARWR), Dyax Corp. (NASDAQ:DYAX)

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings data on Monday. The company reported ($4.98) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $4.60, AnalystRatingsNetwork.com reports. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares after opening at $44.87 moved to $44.87 on last trade day and at the end of the day closed at $42.56.Company price to cash ratio as 20.10. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a negative weekly performance of -26.54%.

Retrophin, Inc. (NASDAQ: RTRX) provided 2014, 2015 revenue guidance well above its prior view. However, the company said despite several investigator-sponsored IND filings for RE-024 in the United States, the FDA has been unwilling to grant a clinical trial through this mechanism.Retrophin Inc (NASDAQ:RTRX) shares advanced 17.89% in last trading session and ended the day on $14.50. RTRX its return on assets is -707.30%. Retrophin Inc (NASDAQ:RTRX) yearly performance is 119.70%.

Arrowhead Research Corp (NASDAQ:ARWR) saw a large growth in short interest in the month of January. As of March 31st, there was short interest totalling 3,296,442 shares, a growth of 50.2% from the March 14th total of 2,194,857 shares,AnalystRatings.Net reports. Currently, 7.4% of the company’s shares are sold short. Based on an average daily trading volume, of 2,514,818 shares, the short-interest ratio is currently 1.3 days.Arrowhead Research Corp (NASDAQ:ARWR) shares moved up 3.07% in last trading session and was closed at $12.77, while trading in range of $11.67-$13.07. Arrowhead Research Corp (NASDAQ:ARWR) year to date performance is 17.70%.

Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 30, 2014. During the call, management will discuss the Company’s financial results for the first quarter 2014 as well as progress regarding its key value drivers – the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.Dyax Corp. (NASDAQ:DYAX) weekly performance is -15.24%. On last trading day company shares ended up $6.73. Dyax Corp. (NASDAQ:DYAX) distance from 50-day simple moving average is -25.89%. Analysts mean target price for the company is $13.36.